Compare MIR & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIR | KRYS |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.3B |
| IPO Year | N/A | 2017 |
| Metric | MIR | KRYS |
|---|---|---|
| Price | $24.56 | $248.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $28.29 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 2.2M | 296.8K |
| Earning Date | 02-10-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 275.72 |
| EPS | 0.10 | ★ 6.66 |
| Revenue | ★ $902,300,000.00 | $373,164,000.00 |
| Revenue This Year | $8.75 | $36.14 |
| Revenue Next Year | $23.17 | $41.80 |
| P/E Ratio | $242.85 | ★ $36.73 |
| Revenue Growth | 7.82 | ★ 54.51 |
| 52 Week Low | $12.00 | $122.80 |
| 52 Week High | $30.28 | $265.92 |
| Indicator | MIR | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 63.53 |
| Support Level | $23.29 | $235.61 |
| Resistance Level | $24.87 | $256.00 |
| Average True Range (ATR) | 0.71 | 7.34 |
| MACD | 0.10 | -1.50 |
| Stochastic Oscillator | 86.36 | 61.27 |
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.